Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-Label, Multicenter, Phase II Clinical Study Evaluating the Efficacy and Safety of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for Participants With HER2-Positive Recurrent or Metastatic Breast Cancer

NCT07545044 is registered in ClinicalTrials.gov with Shanghai JMT-Bio Inc. as lead sponsor.

NCT NCT07545044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-Label, Multicenter, Phase II Clinical Study Evaluating the Efficacy and Safety of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for Participants With HER2-Positive Recurrent or Metastatic Breast Cancer
Lead sponsor
Shanghai JMT-Bio Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 30, 2026
Completion date
May 30, 2027
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive recurrent or metastatic breast cancer